Goldman Sachs’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Goldman Sachs’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,000,000	Closed	-$6.09M	–	7149
2016 Q4	$6.09M	Hold	1,000,000	–	–	﹤0.01%	2885
2016 Q3	$5.51M	Hold	1,000,000	–	–	﹤0.01%	2957
2016 Q2	$3.8M	Sell	1,000,000 -500,000	-33%	-$1.69M	﹤0.01%	3089
2016 Q1	$4.14M	Buy	1,500,000 +1,000,000	+200%	+$3.62M	﹤0.01%	2856
2015 Q4	$2.83M	Hold	500,000	–	–	﹤0.01%	3325
2015 Q3	$2.65M	Buy	+500,000	New	+$3.87M	﹤0.01%	3501

Other funds holding SGYP

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Goldman Sachs's SGYP Position: Q1 2019 in Review

Goldman Sachs sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 722,369 shares — an estimated $82K sold.

Goldman Sachs first reported a position in SGYP in Q2 2013 and held it in 23 quarters. The position peaked at $9.82M in Q2 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

Goldman Sachs reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
Goldman Sachs sold 722,369 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $82K.
Goldman Sachs first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 23 quarters.
Goldman Sachs's Synergy Pharmaceuticals, Inc Common Stock position peaked at $9.82M in Q2 2017.
12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Goldman Sachs's 13F filing for Q1 2019, filed 15 May 2019.